ClinicalTrials.gg
RecruitingNCT07578584Updated Jun 4, 2026

A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity

A Phase 1 interventional study of NNC0497-0040 and Placebo in Type 1 Diabetes (T1D), Overweight and Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.

Planned enrollment
49th of 149
146 · median 62
Started
2026
the only one that year
Phase 1
74 of 226
1 open now
Registered
226th of 226
by date

Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 49th largest by planned enrollment of the 149 interventional ones that give a count, is the only one that started in 2026, is one of 74 in phase 1, and was the 226th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if NNC0497-0040 is safe, tolerable and effective for healthy people living with normal weight or overweight, people living with overweight or obesity and people who have type 1 diabetes and are living with overweight or obesity. There are 2 study treatments in this study, where participants will get either NNC0497-0040, the new treatment being tested or placebo, a treatment that has no active medicine in it. Participants will be in this clinical study for up to 29 weeks.

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Overweight
  • Obesity
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For SAD cohorts

Inclusion Criteria:

  • Female of non- or male aged 18-55 years (both inclusive) at screening.
  • between 18.5 kilogram per m\^2 and 29.9 kilogram per m\^2 (both inclusive) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria:

  • Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • (HbA1c) above or equal to 6.5 percentage (48 millimoles per mole) at screening.
  • Unwilling or unable to refrain from use of prescription medicinal products or non-prescription drugs, including use of herbal products and non-routine vitamins, within 14 days prior to the first day of dosing. Occasional use of paracetamol and ibuprofen to treat acute pain is permitted until 24 hours prior to dosing.

For MAD1-3 cohorts

Inclusion Criteria:

  • Female of non-childbearing potential or male aged 18-55 years (both inclusive) at screening.
  • Body mass index between 27.0 kilogram per m\^2 and 39.9 kilogram per m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria:

  • Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Presence or history of any respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.
  • HbA1c above or equal to 6.5 percentage (48 millimoles per mole) at screening.
  • Unwilling or unable to refrain from use of prescription medicinal products or non-prescription drugs, including use of herbal products and non-routine vitamins, within 14 days prior to the first day of dosing. Occasional use of paracetamol and ibuprofen to treat acute pain is permitted until 24 hours prior to dosing.

For MAD4 cohorts

Inclusion Criteria:

  • Male aged 18-55 years (both inclusive) at screening.
  • Body mass index between 27.0 kilogram per m\^2 and 34.9 kilogram per m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Diagnosed with type 1 diabetes mellitus above or equal to 1 year before screening.
  • Treated with multiple daily insulin injections (daily basal insulin analogue and bolus insulin analogue regimen) more than 90 days prior to the day of screening.
  • Use of continuous glucose monitoring (CGM) device more than 90 consecutive days prior to the day of screening.
  • HbA1c in the range of 7.2percentage - 9.5percentage (both inclusive).

Exclusion Criteria:

  • Any disorder, unwillingness or inability, except for mild conditions under stable treatment associated with type 1 diabetes (T1D), which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus and obesity).
  • Use of any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening or in the period between screening and randomisation.
  • Current treatment with systemically effective , monoamine oxidase (MAO) inhibitors, systemic non-selective beta-blockers or growth hormone.
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or corticosteroids).
  • Unwilling or unable to refrain from use of prescription medicinal products or non-prescription drugs, including use of herbal products and non-routine vitamins, within 14 days prior to the first day of dosing. Occasional use of paracetamol and ibuprofen to treat acute pain is permitted until 24 hours prior to dosing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    SAD

    Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously.

    Drug: NNC0497-0040 · Drug: Placebo

  • Experimental
    MAD1

    Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously.

    Drug: NNC0497-0040 · Drug: Placebo

  • Experimental
    MAD2

    Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously.

    Drug: NNC0497-0040 · Drug: Placebo

  • Experimental
    MAD3

    Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously.

    Drug: NNC0497-0040 · Drug: Placebo

  • Experimental
    MAD4

    Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously.

    Drug: NNC0497-0040 · Drug: Placebo

Interventions

  • DrugNNC0497-0040

    NNC0497-0040 will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    Measured in events

    Time frame: Day 1 up to Week 6

  2. Number of adverse events

    Measured in events

    Time frame: MAD1-2: Day 1 up to Week 17; MAD3: Day 1 up to Week 25

  3. Number of adverse events

    Measured in events

    Time frame: Day 1 up to Week 25

Secondary outcomes

  1. Area under the serum NNC0497-0040 concentration time curve

    Measured in hours \* nanomoles per litre (h\*nmol/L)

    Time frame: Day 1

  2. Cmax: Maximum observed serum NNC0497-0040 concentration

    Measured in nanomoles per litre (nmol/L)

    Time frame: Day 1

  3. Area under the serum NNC0497-0040 concentration time curve at steady state

    Measured in hours \* nanomoles per litre (h\*nmol/L)

    Time frame: MAD1-2: Week 12; MAD3: Week 20

  4. Cmax: Maximum observed serum NNC0497-0040 concentration at steady state

    Measured in nanomoles per litre (nmol/L)

    Time frame: MAD1-2: Week 12; MAD3: Week 20

  5. Number of severe hypoglycaemic episodes

    Measured in events

    Time frame: Day 1 up to Week 25

  6. AUC: Area under the serum NNC0497-0040 concentration time curve during at steady state

    Measured in hours \* nanomoles per litre (h\*nmol/L)

    Time frame: MAD4: Week 20

  7. Cmax: Maximum observed serum NNC0497-0040 concentration at steady state

    Measured in nanomoles per litre (nmol/L)

    Time frame: MAD4: Week 20

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 21 months is above that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
May 7, 2026
Primary completionEst.
Feb 18, 2028
CompletionEst.
Feb 18, 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578584
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 11, 2026
Start date
May 7, 2026
Primary completion
Feb 18, 2028 (estimated)
Completion
Feb 18, 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion